The global neuropathic pain therapeutics market revenue was around US$ 5.8 billion in 2022 and is estimated to reach US$ 10.4 billion by 2031, growing at a compound annual growth rate (CAGR) of 5% during the forecast period from 2023 to 2031.
Neuropathic pain is caused by injury or disease affecting the somatosensory nervous system. This pain is associated with abnormal phenomena called dysesthesia or pain from normally non-painful stimulus. It may have continuous and episodic components. The latter reach electric shocks or stabbings.
Market Driving Factors
The rise in the prevalence of diabetic neuropathy and other targeted diseases drives market growth. Prevalence of peripheral neuropathy is expected to be between 6% and 51% among adults with diabetes depending on age, glucose control, duration of diabetes, type 1, and type 2 diabetes. Diabetic neuropathy is the primary risk factor for the development of diabetic foot ulcers and is implicated in 50% to 75% of non-traumatic amputations.
The surge in the adoption of pain management therapeutics among end users boosts the market. Pain leads to intense complications if proper treatment or care is not taken. Doctors usually prescribe medicines in the initial stages of pain, followed by other treatment options. Prescription drugs are cost-effective and easy to use at a personal level without any ambiguity. Furthermore, surged awareness about available medicines for neuropathic pain management drives the acceptance and consumption of pain management drugs over other treatment options.
Supply-chain difficulties hamper the market growth.
Regional Analysis
North America dominated the market in terms of shares. This can be attributed to the introduction of new drugs and the high prevalence of targeted diseases in developing nations such as the U.S. Furthermore, an increase in the adoption of neuropathic pain therapeutics for treatment and a surge in the number of clinical trials for the development of the products for various disorders boost the region.
Segmentation Insights
Drug Class Insight
The anticonvulsants segment dominated the market and the dominance is likely to continue during the projection period. This can be attributed to the surge in cases of nerve pain and the launch of new drugs. Lyrica is a major brand that dominates the segment.
Indication Insight
The diabetic neuropathy segment is estimated to dominate the market. An article published by the National Centre for Biotechnology Information (NCBI) indicated that the prevalence of neuropathic pain in the public population varies from as little as 1% to as much as 7% to 8%. This contains the maximum incidence in diabetic patients (26%).
Distribution Channel Insight
The retail pharmacies segment dominated the market in terms of revenue and this dominance is projected to continue during the forecast period. The rise in the number of neuropathic pain drugs being dispensed through retail pharmacies and the surge in the number of retail pharmacies in developing nations make these pharmacies a major distribution channel.
Prominent Companies
Segmentation Outline
The global neuropathic pain therapeutics market segmentation focuses on Drug Class, Indication, Route of Administration, Distribution Channel, and Region.
By Drug Class
By Indication
By Route of Administration
By Distribution Channel
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL NEUROPATHIC PAIN THERAPEUTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: NEUROPATHIC PAIN THERAPEUTICS MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL NEUROPATHIC PAIN THERAPEUTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL NEUROPATHIC PAIN THERAPEUTICS MARKET, BY DRUG CLASS
5.1 OVERVIEW
5.2 ANTICONVULSANTS
5.3 ANTIDEPRESSANTS
5.4 NSAIDS
5.5 OPIOIDS
5.6 STEROIDS
5.7 OTHERS
6 GLOBAL NEUROPATHIC PAIN THERAPEUTICS MARKET, BY INDICATION
6.1 OVERVIEW
6.2 DIABETIC NEUROPATHY
6.3 POST-HERPETIC NEURALGIA
6.4 CANCER-RELATED PAIN
6.5 SPINAL CORD INJURY
6.7 OTHERS
7 GLOBAL NEUROPATHIC PAIN THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
7.1 OVERVIEW
7.2 ORAL
7.3 TOPICAL
7.4 OTHERS
8 GLOBAL NEUROPATHIC PAIN THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
8.1 OVERVIEW
8.2 RETAIL PHARMACIES
8.3 HOSPITAL PHARMACIES
8.4 ONLINE PHARMACIES
9 GLOBAL NEUROPATHIC PAIN THERAPEUTICS MARKET, BY GEOGRAPHY
9.1 OVERVIEW
9.2 NORTH AMERICA
9.2.1 NORTH AMERICA MARKET SNAPSHOT
9.2.2 U.S.
9.2.3 CANADA
9.2.4 MEXICO
9.3 EUROPE
9.3.1 EUROPE MARKET SNAPSHOT
9.3.2 WESTERN EUROPE
9.3.2.1 THE UK
9.3.2.2 GERMANY
9.3.2.3 FRANCE
9.3.2.4 ITALY
9.3.2.5 SPAIN
9.3.2.6 REST OF WESTERN EUROPE
9.3.3 EASTERN EUROPE
9.3.3.1 POLAND
9.3.3.2 RUSSIA
9.3.3.3 REST OF EASTERN EUROPE
9.4 ASIA PACIFIC
9.4.1 ASIA PACIFIC MARKET SNAPSHOT
9.4.2 CHINA
9.4.3 JAPAN
9.4.4 INDIA
9.4.5 AUSTRALIA & NEW ZEALAND
9.4.6 ASEAN
9.4.7 REST OF ASIA PACIFIC
9.5 MIDDLE EAST & AFRICA
9.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
9.5.2 UAE
9.5.3 SAUDI ARABIA
9.5.4 SOUTH AFRICA
9.5.5 REST OF MEA
9.6 SOUTH AMERICA
9.6.1 SOUTH AMERICA MARKET SNAPSHOT
9.6.2 BRAZIL
9.6.3 ARGENTINA
9.6.4 REST OF SOUTH AMERICA
10 GLOBAL NEUROPATHIC PAIN THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 COMPANY MARKET RANKING
10.3 KEY DEVELOPMENT STRATEGIES
10.4 COMPETITIVE DASHBOARD
10.5 PRODUCT MAPPING
10.6 TOP PLAYER POSITIONING, 2022
10.7 COMPETITIVE HEATMAP
10.8 TOP WINNING STRATEGIES
11 COMPANY PROFILES
11.1 PFIZER
11.1.1 OVERVIEW
11.1.2 FINANCIAL PERFORMANCE
11.1.3 PRODUCT OUTLOOK
11.1.4 KEY DEVELOPMENTS
11.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.2 NOVARTIS AG
11.2.1 OVERVIEW
11.2.2 FINANCIAL PERFORMANCE
11.2.3 PRODUCT OUTLOOK
11.2.4 KEY DEVELOPMENTS
11.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.3 ASTRAZENECA
11.3.1 OVERVIEW
11.3.2 FINANCIAL PERFORMANCE
11.3.3 PRODUCT OUTLOOK
11.3.4 KEY DEVELOPMENTS
11.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.4 GLAXOSMITHKLINE
11.4.1 OVERVIEW
11.4.2 FINANCIAL PERFORMANCE
11.4.3 PRODUCT OUTLOOK
11.4.4 KEY DEVELOPMENTS
11.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.5 ELI LILLY AND COMPANY
11.5.1 OVERVIEW
11.5.2 FINANCIAL PERFORMANCE
11.5.3 PRODUCT OUTLOOK
11.5.4 KEY DEVELOPMENTS
11.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.6 MALLINCKRODT PHARMACEUTICALS
11.6.1 OVERVIEW
11.6.2 FINANCIAL PERFORMANCE
11.6.3 PRODUCT OUTLOOK
11.6.4 KEY DEVELOPMENTS
11.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.7 JOHNSON & JOHNSON
11.7.1 OVERVIEW
11.7.2 FINANCIAL PERFORMANCE
11.7.3 PRODUCT OUTLOOK
11.7.4 KEY DEVELOPMENTS
11.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.8. ABBOTT
11.8.1 OVERVIEW
11.8.2 FINANCIAL PERFORMANCE
11.8.3 PRODUCT OUTLOOK
11.8.4 KEY DEVELOPMENTS
11.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.9 ENDO PHARMACEUTICALS INC
11.9.1 OVERVIEW
11.9.2 FINANCIAL PERFORMANCE
11.9.3 PRODUCT OUTLOOK
11.9.4 KEY DEVELOPMENTS
11.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.10 TEVA PHARMACEUTICAL INDUSTRIES LIMITED
11.10.1 OVERVIEW
11.10.2 FINANCIAL PERFORMANCE
11.10.3 PRODUCT OUTLOOK
11.10.4 KEY DEVELOPMENTS
11.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
11.11 MERCK & CO. INC
11.11.1 OVERVIEW
11.11.2 FINANCIAL PERFORMANCE
11.11.3 PRODUCT OUTLOOK
11.11.4 KEY DEVELOPMENTS
11.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved